Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes, Validating Neoadjuvant Therapies, and Improving Precision-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Artificial Intelligence Enhances NSCLC Care by Predicting Treatment Outcomes, Validating Neoadjuvant Therapies, and Improving Precision

Published:2024-05 Issue:5 Volume:19 Page:666-667
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Ishikawa Shumpei

Funder

AMED

Publisher

Elsevier BV

Reference11 articles.

1. Artificial intelligence-powered assessment of pathologic response to neoadjuvant atezolizumab in patients with NSCLC: results from the LCMC3 study;Dacic;J Thorac Oncol,2024

2. Neoadjuvant atezolizumab for resectable non-small cell lung cancer: an open-label, single-arm phase II trial;Chaft;Nat Med,2022

3. Safety and efficacy of neoadjuvant immune checkpoint inhibitor therapy in patients with resectable non-small-cell lung cancer: a systematic review;Zhao;Target Oncol,2021

4. Neoadjuvant nivolumab plus chemotherapy in resectable lung cancer;Forde;N Engl J Med,2022

5. Adjuvant and neoadjuvant use of immune checkpoint inhibitors in NSCLC;Walia;J Cancer Res Clin Oncol,2023

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP